TP53 and non-small cell lung carcinoma: In our study, we chose Hcc827 and H292 (TP53 mutant and WT) cells for the in vivo experiments, and the FOXO4-DRI were used to target senescence-like CAFs in order to reduce NSCLC cells’ radioresistance.